Detail akcie Organgnss Hldg Rg-A online

Business Summary: Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Organogenesis Holdings Inc revenues increased 17% to $564.2M. Net income applicable to common stockholders totaled $20M vs. loss of $937K. Revenues reflect Advanced Wound Care segment increase of 17% to $531.2M, Surgical & Sports Medicine segment increase of 12% to $31.8M. Net Income reflects Impairment of property and construction decrease from $18.8M (expense) to $0K.